

Andreas Willerslev-Olsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2244842/publications.pdf>

Version: 2024-02-01

27
papers

1,013
citations

430874
18
h-index

526287
27
g-index

27
all docs

27
docs citations

27
times ranked

1169
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood, 2019, 134, 1072-1083.	1.4	94
2	Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood, 2016, 127, 1287-1296.	1.4	86
3	Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood, 2013, 122, 943-950.	1.4	78
4	Single-cell heterogeneity in SÅ©zary syndrome. Blood Advances, 2018, 2, 2115-2126.	5.2	78
5	Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. Oncotarget, 2015, 6, 20555-20569.	1.8	78
6	Butyrate and propionate inhibit antigen-specific CD8 ⁺ T cell activation by suppressing IL-12 production by antigen-presenting cells. Scientific Reports, 2017, 7, 14516.	3.3	77
7	Bacterial Toxins Fuel Disease Progression in Cutaneous T-Cell Lymphoma. Toxins, 2013, 5, 1402-1421.	3.4	66
8	Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood, 2014, 124, 761-770.	1.4	59
9	Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. Blood, 2018, 131, 759-770.	1.4	54
10	STAT5 induces miR-21 expression in cutaneous T cell lymphoma. Oncotarget, 2016, 7, 45730-45744.	1.8	45
11	SATB1 in Malignant T Cells. Journal of Investigative Dermatology, 2018, 138, 1805-1815.	0.7	38
12	Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4 ⁺ T cells in cutaneous T-cell lymphoma. OncoImmunology, 2019, 8, e1641387.	4.6	32
13	Cellular Interactions and Inflammation in the Pathogenesis of Cutaneous T-Cell Lymphoma. Frontiers in Cell and Developmental Biology, 2020, 8, 851.	3.7	28
14	MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas. Cancers, 2020, 12, 1229.	3.7	28
15	IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF). Cell Cycle, 2014, 13, 1306-1312.	2.6	27
16	<i>Staphylococcus aureus</i> alpha-toxin inhibits CD8 ⁺ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma. OncoImmunology, 2020, 9, 1751561.	4.6	24
17	Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in SÅ©zary syndrome. Blood Cancer Journal, 2020, 10, 57.	6.2	24
18	A novel BLK-induced tumor model. Tumor Biology, 2017, 39, 101042831771419.	1.8	19

#	ARTICLE	IF	CITATIONS
19	JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL). <i>Cancers</i> , 2021, 13, 280.	3.7	17
20	Staphylococcus aureus Induces Signal Transducer and Activator of Transcription 5' Dependent miR-155 Expression in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2449-2458.	0.7	15
21	STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides. <i>Anticancer Research</i> , 2014, 34, 5277-86.	1.1	15
22	The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma. <i>Dermatology</i> , 2021, 237, 283-290.	2.1	8
23	MicroRNA-93 Targets p21 and Promotes Proliferation in Mycosis Fungoides T Cells. <i>Dermatology</i> , 2021, 237, 277-282.	2.1	8
24	Skin Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL. <i>Blood</i> , 2019, 134, 659-659.	1.4	5
25	The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 866-869.	0.7	4
26	Expression of the Voltage-Gated Potassium Channel Kv1.3 in Lesional Skin from Patients with Cutaneous T-Cell Lymphoma and Benign Dermatitis. <i>Dermatology</i> , 2020, 236, 123-132.	2.1	3
27	Expression and function of Kv1.3 channel in malignant T cells in SÅ©zary syndrome. <i>Oncotarget</i> , 2019, 10, 4894-4906.	1.8	3